WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Virulence-Related Factors and Antibiotic Resistance Patterns of Proteus Species in Urinary Tract Infections.

Ms. Samrin Hayath[1], Dr. Mandha Swathi[2]

[1] Research Scholar, Malwanchal University, Indore.
[2] Research Supervisor, Malwanchal University, Indore.

Introduction :

Urinary tract infections (UTIs) are one of the most common infections affecting individuals globally, and Proteus species are significant pathogens in this regard. Among the Proteus species, Proteus mirabilis is the most frequently implicated in UTIs. The increasing prevalence of antibiotic-resistant strains of Proteus species poses a severe challenge to the treatment and management of UTIs. Understanding the virulence-related factors that contribute to antibiotic resistance in Proteus species is crucial for developing effective therapeutic strategies.[1]

Overview of Proteus Species

Proteus species are Gram-negative, facultatively anaerobic bacteria belonging to the family Enterobacteriaceae. They are known for their swarming motility and ability to produce urease, an enzyme that hydrolyzes urea to ammonia, creating an alkaline environment conducive to stone formation in the urinary tract. The primary species causing UTIs include Proteus mirabilis, Proteus vulgaris, and Proteus penneri. Among these, P. mirabilis is the most clinically significant.[2]

Virulence Factors of Proteus Species

Several virulence factors enable Proteus species to colonize, invade, and cause disease in the urinary tract:

1. **Urease Production**: Urease is a key virulence factor in Proteus species. By hydrolyzing urea into ammonia and carbon dioxide, urease increases the urine pH, leading to the precipitation of magnesium and calcium ions, which form kidney stones (struvite and apatite). These stones can obstruct the urinary tract, facilitating bacterial persistence and infection.
2. **Swarming Motility**: Swarming motility allows Proteus species to migrate across the surface of the urinary tract, forming biofilms that protect the bacteria from the host immune response and antibiotic treatment. Swarming cells are highly flagellated and can move in coordinated groups, spreading the infection.
3. **Fimbriae and Adhesins**: Proteus species possess various fimbriae and adhesins that facilitate attachment to host tissues. The most well-studied fimbriae in P. mirabilis are the mannose-resistant Proteus-like (MR/P) fimbriae, which bind to uroepithelial cells and extracellular matrix proteins, promoting colonization and biofilm formation.[3]
4. **Hemolysins**: Proteus species produce hemolysins, such as hemolysin A (HpmA), which lyse host cells, releasing nutrients that the bacteria can utilize. Hemolysins also contribute to tissue damage and inflammation, exacerbating the infection.
5. **Proteases**: Proteases, such as ZapA, degrade host proteins, including immunoglobulins and complement proteins, impairing the host immune response. This helps the bacteria evade the immune system and establish infection.

Antibiotic Resistance in Proteus Species

Proteus species exhibit various mechanisms of antibiotic resistance, complicating the treatment of UTIs. The resistance patterns are often multifactorial, involving genetic and biochemical factors:

1. **Beta-Lactamase Production**: One of the primary mechanisms of resistance is the production of beta-lactamases, enzymes that hydrolyze the beta-lactam ring of antibiotics such as penicillins and cephalosporins. Extended-spectrum beta-lactamases (ESBLs) and AmpC beta-lactamases are commonly produced by Proteus species, rendering them resistant to a wide range of beta-lactam antibiotics.
2. **Efflux Pumps**: Efflux pumps are membrane proteins that actively expel antibiotics from the bacterial cell, reducing their intracellular concentration and effectiveness. Proteus species possess various efflux pump systems, such as AcrAB-TolC, which confer resistance to multiple antibiotic classes, including quinolones, tetracyclines, and chloramphenicol.

3. **Porin Alterations**: Alterations in the outer membrane porins can decrease the uptake of antibiotics, particularly beta-lactams and aminoglycosides. Mutations or downregulation of porins such as OmpF and OmpC can contribute to resistance by limiting antibiotic entry into the bacterial cell.[4]
4. **Target Site Modifications**: Proteus species can acquire mutations in the target sites of antibiotics, reducing their binding affinity and efficacy. For example, mutations in the DNA gyrase or topoisomerase IV genes can confer resistance to fluoroquinolones. Similarly, modifications in ribosomal proteins or RNA can lead to resistance to macrolides, aminoglycosides, and tetracyclines.
5. **Enzymatic Inactivation**: Apart from beta-lactamases, Proteus species produce other enzymes that inactivate antibiotics. For instance, aminoglycoside-modifying enzymes (AMEs) acetylate, phosphorylate, or adenylate aminoglycosides, rendering them ineffective.[5]

Relationship Between Virulence Factors and Antibiotic Resistance

The interplay between virulence factors and antibiotic resistance in Proteus species is complex and multifaceted. Several virulence factors contribute directly or indirectly to antibiotic resistance:

1. **Biofilm Formation**: Biofilms provide a protective environment for bacteria, shielding them from antibiotics and the host immune system. The dense extracellular matrix of biofilms can impede antibiotic penetration, while the presence of persister cells within biofilms can survive antibiotic treatment and repopulate the infection site.
2. **Swarming Motility**: Swarming cells exhibit phenotypic changes that enhance their resistance to antibiotics. During swarming, Proteus species upregulate efflux pumps and produce extracellular matrix components, contributing to increased antibiotic tolerance.
3. **Urease Activity**: The alkaline environment created by urease activity can affect the efficacy of certain antibiotics. For instance, aminoglycosides are less effective at higher pH levels. Additionally, the formation of kidney stones can serve as a nidus for bacterial persistence and antibiotic resistance.
4. **Protease Production**: Proteases can degrade antimicrobial peptides and host defense proteins, reducing the effectiveness of the innate immune response. This enables the bacteria to survive and proliferate despite the presence of antibiotics.
5. **Fimbriae and Adhesins**: The ability of Proteus species to adhere to host tissues and form biofilms enhances their persistence and resistance. Biofilm-associated cells exhibit different gene expression profiles, including upregulation of resistance genes, compared to planktonic cells.[6]

Clinical Implications and Treatment Strategies

The increasing prevalence of antibiotic-resistant Proteus species in UTIs necessitates the development of effective treatment strategies. Clinicians must consider both the virulence factors and resistance mechanisms when selecting appropriate therapies:

1. **Combination Therapy**: Using a combination of antibiotics with different mechanisms of action can enhance treatment efficacy and reduce the likelihood of resistance development. For example, combining a beta-lactam antibiotic with a beta-lactamase inhibitor can overcome beta-lactamase-mediated resistance.[7]
2. **Novel Antibiotics**: The development of new antibiotics with unique targets or mechanisms of action is crucial for combating resistant Proteus species. Research into antimicrobial peptides, bacteriophages, and other alternative therapies holds promise for future treatments.[8]
3. **Adjuvant Therapy**: Adjunctive therapies that target virulence factors, such as urease inhibitors or biofilm-disrupting agents, can enhance the effectiveness of antibiotics. By weakening the bacteria's defense mechanisms, these therapies can improve antibiotic penetration and efficacy.[9]
4. **Antimicrobial Stewardship**: Rational use of antibiotics and antimicrobial stewardship programs are essential to minimize the development and spread of resistance. This includes appropriate antibiotic selection, dosing, and duration of therapy, as well as infection control measures to prevent transmission.[10]
5. **Diagnostic Advances**: Rapid and accurate diagnostic tools can help identify antibiotic-resistant Proteus species and their virulence factors, guiding targeted treatment decisions. Molecular techniques such as PCR and whole-genome sequencing can provide valuable insights into resistance mechanisms and epidemiology.[11]

Conclusion :

Proteus species are significant pathogens in UTIs, and their virulence factors and antibiotic resistance mechanisms pose considerable challenges to treatment. The interplay between virulence factors, such as biofilm formation, swarming motility, and urease activity, and resistance mechanisms, including beta-lactamase production, efflux pumps, and target site modifications, complicates therapeutic strategies. Understanding these complex interactions is crucial for developing effective treatments and mitigating the impact of antibiotic resistance in Proteus species. Through a combination of novel antibiotics, adjuvant therapies, antimicrobial stewardship, and advanced diagnostics, it is possible to improve the management of UTIs caused by these resilient pathogens.

REFERENCE :

1. Algammal, A. M., Hashem, H. R., Alfifi, K. J., Hetta, H. F., Sheraba, N. S., Ramadan, H., et al. (2021). atpD gene sequencing, multidrug resistance traits, virulence-determinants, and antimicrobial resistance genes of emerging XDR and MDR-*Proteus mirabilis*. *Sci. Rep.* 11:9476. doi: 10.1038/s41598-021-88861-w

2. Durgadevi, R., Kaleeshwari, R., Swetha, T. K., Alexpandi, R., Pandian, S. K., and Ravi, A. V. (2020). Attenuation of *Proteus mirabilis* colonization and swarming motility on indwelling urinary catheter by antibiofilm impregnation: an in vitro study. *Colloids Surf. B: Biointerfaces* 194:111207. doi: 10.1016/j.colsurfb.2020.111207
3. Filipiak, A., Chrapek, M., Literacka, E., Wawszczak, M., Głuszek, S., Majchrzak, M., et al. (2020). Pathogenic factors correlate with antimicrobial resistance among clinical *Proteus mirabilis* strains. *Front. Microbiol.* 11:579389. doi: 10.3389/fmicb.2020.579389
4. Gaastra, W., Van Oosterom, R. A. A., Pieters, E. W. J., Bergmans, H. E. N., Van Dijk, L., Agnes, A., et al. (1996). Isolation and characterisation of dog uropathogenic *Proteus mirabilis* strains. *Vet. Microbiol.* 48, 57–71. doi: 10.1016/0378-1135(95)00133-6
5. Gao, H., Gao, Y., Yang, C., Dong, D., Yang, J., Peng, G., et al. (2018). Influence of outer membrane vesicles of *Proteus mirabilis* isolated from boar semen on sperm function. *Vet. Microbiol.* 224, 34–42. doi: 10.1016/j.vetmic.2018.08.017
6. Girlich, D., Bonnin, R. A., Dortet, L., and Naas, T. (2020). Genetics of acquired antibiotic resistance genes in *Proteus spp*. *Front. Microbiol.* 11:256. doi: 10.3389/fmicb.2020.00256
7. Guo, W., Mishra, S., Wang, C., Zhang, H., Ning, R., Kong, F., et al. (2019). Comparative study of gut microbiota in wild and captive Giant pandas (*Ailuropoda melanoleuca*). *Genes (Basel)* 10:E827. doi: 10.3390/genes10100827
8. Harada, K., Niina, A., Shimizu, T., Mukai, Y., Kuwajima, K., Miyamoto, T., et al. (2014). Phenotypic and molecular characterization of antimicrobial resistance in *Proteus mirabilis* isolates from dogs. *J. Med. Microbiol.* 63, 1561–1567. doi: 10.1099/jmm.0.081539-0
9. Hu, R., Wang, X., Muhamamd, I., Wang, Y., Dong, W., Zhang, H., et al. (2020). Biological characteristics and genetic analysis of a highly pathogenic *Proteus Mirabilis* strain isolated from dogs in China. *Front. Vet. Sci.* 7:589. doi: 10.3389/fvets.2020.00589
10. Hughes, D., and Andersson, D. I. (2017). Environmental and genetic modulation of the phenotypic expression of antibiotic resistance. *FEMS Microbiol. Rev.* 41, 374–391. doi: 10.1093/femsre/fux0004
11. Khoramian, B., Jabalameli, F., Niasari-Naslaji, A., Taherikalani, M., and Emaneini, M. (2015). Comparison of virulence factors and biofilm formation among *Staphylococcus aureus* strains isolated from human and bovine infections. *Microb. Pathog.* 88, 73–77. doi: 10.1016/j.micpath.2015.08.007